LONGEVA.

RESEARCH PEPTIDES

TIRZEPATIDE

GIP / GLP-1 RECEPTOR AGONIST

≥ 99% PURITY · JANOSHIK COA

longeva.bio

FOR RESEARCH & LABORATORY USE ONLY · NOT FOR HUMAN CONSUMPTION

WHAT IS IT?

Tirzepatide is a dual GIP and GLP-1 receptor agonist — a single peptide that engages two incretin pathways. It is widely studied in the scientific literature for its role in glucose regulation and energy metabolism, and is supplied as a lyophilised powder for laboratory reconstitution.

Mechanism

Dual GIP + GLP-1
receptor agonist;
two incretin pathways.

Research interest

A leading dual-incretin
peptide in current
metabolic research.

This document is provided for research and informational purposes only.
It is not medical advice and makes no human-use claims.

RESEARCH CONTEXT

Areas explored in the peer-reviewed literature include:

- Dual GIP/GLP-1 receptor engagement and signalling
- Glucose-dependent insulin response and glycaemic regulation
- Energy-balance and appetite-signalling pathways

QUALITY & TESTING

Verified purity

> 99% by HPLC on
every production batch.

Janoshik COA

Independent third-party
certificate of analysis.

Storage

Lyophilised: 2–8 °C.
Reconstituted: 2–8 °C.

Handling

Protect from light;
avoid freeze–thaw cycles.

SPECIFICATIONS

Substance	**Tirzepatide**
CAS	**2023788-19-2**
Form	**Lyophilised powder**
Purity	**> 99% (HPLC)**
Sizes	**5 / 10 / 30 mg per vial**
Storage	**2–8 °C**

RECONSTITUTION

Add bacteriostatic water (e.g. 2 ml for a 5 mg vial → 2.5 mg/ml). Swirl gently — do not shake — and draw on a U-100 insulin syringe. Full calculator & step-by-step guide at longeva.bio.

FAQ

How is purity verified?

HPLC on each batch, with an independent Janoshik COA.

What solvent is used?

Bacteriostatic water for reconstitution in the lab.

Is it for human use?

No — research & laboratory use only.